Abstract: Secondary carbon batteries are attractive from an environmental perspective, as they have carbon-only electrodes and are therefore metal-free. Current invention refers to novel secondary carbon batteries with water-based brine electrolytes. These electrolytes have low toxicity, are not flammable, and allow for easy on-site battery recycling. The inventive carbon batteries feature graphite current collectors, activated carbon electrodes, and aqueous eutectic electrolytes comprising NaCl, KCl, MgCl2, or CaCl2. Further improvement of the batteries is performed by an initial repetitive charge-discharge cycling with subsequent replacement of the spent electrolyte. The improved secondary carbon batteries with the operating voltage of about 1.8 V can be used for electric storage utilities of renewable energy installations.

Abstract: Novel pulsed aluminum batteries (PAlBs), including power output regulated systems, have been developed. PAlBs comprise an aluminum anode, a cathode, and a complex electrolyte containing bases, facilitating and stabilizing agents, and may contain internal oxidizers. The aluminum anode comprises technical grade or recycled aluminum. The cathode may comprise copper, nickel, or platinum. Bases may comprise sodium or potassium hydroxide. Facilitating and stabilizing agents may comprise sodium and lithium chlorides or sulfates. Internal oxidizers may comprise sodium hypochlorite. Frequency of electric pulses in novel PAlBs can be controlled by electric or chemical means. PAlBs can be used as components of backup power systems, in unmanned aerial vehicles (UAVs), and in autonomous self-powered electrochemical computing systems and sensors.

Abstract: Novel pulsed aluminum batteries (PAlBs), including power output regulated systems, have been developed. PAlBs comprise an aluminum anode, a cathode, and a complex electrolyte containing bases, facilitating and stabilizing agents, and may contain internal oxidizers. The aluminum anode comprises technical grade or recycled aluminum. The cathode may comprise copper, nickel, or platinum. Bases may comprise sodium or potassium hydroxide. Facilitating and stabilizing agents may comprise sodium and lithium chlorides or sulfates. Internal oxidizers may comprise sodium hypochlorite. Frequency of electric pulses in novel PAlBs can be controlled by electric or chemical means. PAlBs can be used as components of backup power systems, in unmanned aerial vehicles (UAVs), and in autonomous self-powered electrochemical computing systems and sensors.

Abstract: The present disclosure relates to novel compounds that can be used as anti-cancer agents in the prostate cancer therapy. In particular, the invention relates to N-acyl derivatives of 2,3-dihydro-1H-pyrrolo[2,3-b]quinolines having the structural Formula (I), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or pharmaceutically acceptable salt and/or solvate thereof. The meaning of R1 is independently selected from H; C1-C6 Alkyl, cyclo-Alkyl or iso-Alkyl substituents; R2 is selected from C1-C6 Alkyl, cyclo-Alkyl or iso-Alkyl; substituted or non-substituted, fused or non-fused to substituted or non-substituted aromatic ring, aryl or heteroaryl groups. The invention also relates to methods for preparing said compounds, and to pharmaceutical compositions comprising said compounds.

Abstract: The present disclosure relates to novel compounds that can be used as anti-cancer agents in the prostate cancer therapy. In particular, the invention relates N-substituted derivatives of 4-(hetero)aryl-1,2,5-oxadiazol-3-yl amines having the structural Formula (I) and (II), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or pharmaceutically acceptable salt and/or solvate thereof. Meaning of R1 and R2 in the Formula (I) and (II) are defined in claim 1. The invention also relates to methods for preparing said compounds, and to pharmaceutical compositions comprising said compounds.

Abstract: The present disclosure relates to novel compounds having the structural Formulas (1a,1b), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or pharmaceutically acceptable salt and/or solvate thereof as chemotherapy agents for treating of cancer, particularly androgen-independent prostate cancer. The disclosure also relates to methods for preparing said compounds, and to pharmaceutical compositions comprising said compounds.

Abstract: The present disclosure relates to novel compounds having the structural Formulas (1a,1b), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or pharmaceutically acceptable salt and/or solvate thereof as chemotherapy agents for treating of cancer, particularly androgen-independent prostate cancer. The disclosure also relates to methods for preparing said compounds, and to pharmaceutical compositions comprising said compounds.